RxDoctor Payments Data

Emily Edwards

Optometrist · Cedarcreek, MONPI 1235582313

Payments from drug & device makers

$5,787in general payments, 2019–2025

Across 114 payments — averaging $50.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$2K
  • Coopervision Inc.$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
  • Sun Pharmaceutical Industries Inc.$356
  • Sight Sciences, Inc.$295
  • AbbVie$260
  • plus $838 from 11 others

What the payments were for

  • Speaking & faculty fees$992%
  • Food & beverage$5,68898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,787 in reported general payments places this provider in the 90th percentile of 1,030 optometrist providers in Missouri.

See all optometrist providers in Missouri

Medicare billing

Part B allowed, 2024
$97,740
Medicare patients
505
Services billed
1,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast20$34,782
RestasisCyclosporine25$31,649
Cyclosporine25$11,087
LumiganBimatoprost18$9,924
SimbrinzaBrinzolamide/Brimonidine Tart34$8,116
Brimonidine Tartrate39$2,425
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$2,399
Prednisolone Acetate83$1,800
Latanoprost295$1,768
Tobramycin-DexamethasoneTobramycin/Dexamethasone37$1,453
Azelastine Hcl69$989
Travoprost15$745
Timolol Maleate141$698
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat55$570
Dorzolamide Hcl15$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$260$41,57343 claims
Bausch & Lomb Americas Inc.Xiidra$1,690$34,78220 claims
AlconSimbrinza$78$8,11634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,030 optometrist providers in Missouri.

Other optometrist in Cedarcreek

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →